Long-term use of an LH-RH agonist in the management of uterine leiomyomas: a study of 17 cases.

George M, Lhomme C, Lefort J, Gras C, Comaru-Schally AM, Schally AV

International journal of fertility1 Jan 1989Cited by 19 (Europe PMC)

PMID2565299PepBankPUB-02565299

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In women with myomas, estradiol fell to a mean of 17.3 pg/mL during Decapeptyl treatment.
In plain wordsIn women with myomas, estradiol fell during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseSerum estradiol
Study
n = 17
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
100 micrograms/day · intramuscular · mean 4.7 monthsAs given in this study (human).
Measurements
Mean serum estradiol
17.3 pg/mL
during Decapeptyl treatment
Serum estradiol range
5 to 80 pg/mL
during Decapeptyl treatment
Source sentences
Summary
In all patients, the pituitary-ovarian axis was suppressed after 1 month of treatment, and mean serum estradiol levels fell to 17.3 pg/mL (range, 5-80).
3 context sentences(design, population, supporting numbers)
Summary · context
Seventeen nonmenopausal women with symptomatic uterine myomas, diagnosed by clinical examination and confirmed by pelvic ultrasonography, were treated with a delayed-release microcapsule preparation of D-Trp-6-LH-RH (Decapeptyl) injected intramuscularly, every 28 days.
Summary · context
The microcapsules were designed to release 100 micrograms/day for 30 days.
Summary · context
The mean duration of treatment was 4.7 months (range, 1-11).
Report a problemFND-0256529902
02HumanNon-randomized trialEfficacy outcome
In women with myomas, serum LH did not change significantly during Decapeptyl treatment.
In plain wordsIn women with myomas, LH did not change significantly during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeSerum LH
Study
n = 17
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
100 micrograms/day · intramuscular · mean 4.7 monthsAs given in this study (human).
Source sentences
Summary
There were no significant changes in serum LH and FSH levels.
3 context sentences(design, population, supporting numbers)
Summary · context
Seventeen nonmenopausal women with symptomatic uterine myomas, diagnosed by clinical examination and confirmed by pelvic ultrasonography, were treated with a delayed-release microcapsule preparation of D-Trp-6-LH-RH (Decapeptyl) injected intramuscularly, every 28 days.
Summary · context
The microcapsules were designed to release 100 micrograms/day for 30 days.
Summary · context
The mean duration of treatment was 4.7 months (range, 1-11).
Report a problemFND-0256529903
03HumanNon-randomized trialEfficacy outcome
In women with myomas, serum FSH did not change significantly during Decapeptyl treatment.
In plain wordsIn women with myomas, FSH did not change significantly during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeSerum FSH
Study
n = 17
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
100 micrograms/day · intramuscular · mean 4.7 monthsAs given in this study (human).
Source sentences
Summary
There were no significant changes in serum LH and FSH levels.
3 context sentences(design, population, supporting numbers)
Summary · context
Seventeen nonmenopausal women with symptomatic uterine myomas, diagnosed by clinical examination and confirmed by pelvic ultrasonography, were treated with a delayed-release microcapsule preparation of D-Trp-6-LH-RH (Decapeptyl) injected intramuscularly, every 28 days.
Summary · context
The microcapsules were designed to release 100 micrograms/day for 30 days.
Summary · context
The mean duration of treatment was 4.7 months (range, 1-11).
Report a problemFND-0256529904
04HumanNon-randomized trialEfficacy outcome
In women with myomas, 15 patients (83%) reported symptom improvement during Decapeptyl treatment.
In plain wordsIn women with myomas, 15 patients reported symptom improvement during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseSymptom improvement
Study
n = 17
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
100 micrograms/day · intramuscular · mean 4.7 monthsAs given in this study (human).
Measurements
Patients with symptom improvement
15 patients
Decapeptyl-treated women
Proportion with symptom improvement
83%
Decapeptyl-treated women
Source sentences
Summary
Fifteen patients (83%) experienced an improvement of such symptoms as abdominal pain and bleeding.
3 context sentences(design, population, supporting numbers)
Summary · context
Seventeen nonmenopausal women with symptomatic uterine myomas, diagnosed by clinical examination and confirmed by pelvic ultrasonography, were treated with a delayed-release microcapsule preparation of D-Trp-6-LH-RH (Decapeptyl) injected intramuscularly, every 28 days.
Summary · context
The microcapsules were designed to release 100 micrograms/day for 30 days.
Summary · context
The mean duration of treatment was 4.7 months (range, 1-11).
Report a problemFND-0256529905
05HumanNon-randomized trialEfficacy outcome
During Decapeptyl treatment, uterine size decreased in 81% of women, and 38% of these responders had uterine volume reductions exceeding 50%.
In plain wordsIn women with myomas, uterine size decreased in 81% during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseUterine volume reduction
Study
n = 17
Outcome group
Tumor growth · Reproductive and sexual health
Studied dose
100 micrograms/day · intramuscular · mean 4.7 monthsAs given in this study (human).
Measurements
Patients with decreased uterine size
81%
enlarged uteri during treatment
Patients with uterine volume decrease more than 50%
38%
among patients with decreased uterine size
Source sentences
Summary
Enlarged uteri decreased in 81% of patients during the treatment, and in 38% of them the decrease in uterine volume was more than 50%.
3 context sentences(design, population, supporting numbers)
Summary · context
Seventeen nonmenopausal women with symptomatic uterine myomas, diagnosed by clinical examination and confirmed by pelvic ultrasonography, were treated with a delayed-release microcapsule preparation of D-Trp-6-LH-RH (Decapeptyl) injected intramuscularly, every 28 days.
Summary · context
The microcapsules were designed to release 100 micrograms/day for 30 days.
Summary · context
The mean duration of treatment was 4.7 months (range, 1-11).
Report a problemFND-0256529906
06HumanNon-randomized trialEfficacy outcome
After Decapeptyl treatment for myomas, eight women required no additional therapy, four underwent surgery, and the others received progestins.
In plain wordsAfter Decapeptyl for myomas, eight women required no further therapy, four had surgery, and others received progestins.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableSubsequent therapy
Study
n = 17
Outcome group
Tumor growth · Reproductive and sexual health
Studied dose
100 micrograms/day · intramuscular · mean 4.7 monthsAs given in this study (human).
Measurements
Patients needing no additional therapy
8 patients
after Decapeptyl
Patients who underwent surgery
4 patients
after Decapeptyl
Source sentences
Summary
After Decapeptyl, eight patients did not require any additional therapy, four underwent surgery, and the others were treated with progestins.
3 context sentences(design, population, supporting numbers)
Summary · context
Seventeen nonmenopausal women with symptomatic uterine myomas, diagnosed by clinical examination and confirmed by pelvic ultrasonography, were treated with a delayed-release microcapsule preparation of D-Trp-6-LH-RH (Decapeptyl) injected intramuscularly, every 28 days.
Summary · context
The microcapsules were designed to release 100 micrograms/day for 30 days.
Summary · context
The mean duration of treatment was 4.7 months (range, 1-11).
Report a problemFND-0256529908
07HumanNon-randomized trialSafety outcome
In women with myomas, Decapeptyl side effects were mild and mainly hot flushes.
In plain wordsIn women with myomas, Decapeptyl side effects were mild and mainly hot flushes.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableHot flushes
Study
n = 17
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
100 micrograms/day · intramuscular · mean 4.7 monthsAs given in this study (human).
Source sentences
Summary
The side effects were mild, consisting mainly of hot flushes.
3 context sentences(design, population, supporting numbers)
Summary · context
Seventeen nonmenopausal women with symptomatic uterine myomas, diagnosed by clinical examination and confirmed by pelvic ultrasonography, were treated with a delayed-release microcapsule preparation of D-Trp-6-LH-RH (Decapeptyl) injected intramuscularly, every 28 days.
Summary · context
The microcapsules were designed to release 100 micrograms/day for 30 days.
Summary · context
The mean duration of treatment was 4.7 months (range, 1-11).
Report a problemFND-0256529909
08HumanNon-randomized trialEfficacy outcome
During Decapeptyl treatment, 2 of 12 myomas disappeared and 9 shrank, with 7 decreasing by more than 50%.
In plain wordsIn women with myomas, 2 tumors disappeared and 9 shrank during Decapeptyl treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseMyoma disappearance and volume reduction
Study
n = 10
Outcome group
Tumor growth · Reproductive and sexual health
Studied dose
100 micrograms/day · intramuscular · mean 4.7 monthsAs given in this study (human).
Measurements
Myomas that disappeared
2 myomas
during treatment
Myomas that decreased in volume
9 myomas
during treatment
Myomas with decrease more than 50%
7 myomas
during treatment
Source sentences
Summary
Among the 12 myomas found in 10 women, 2 disappeared and 9 decreased in volume during the treatment; for 7 myomas the decrease was more than 50%.
3 context sentences(design, population, supporting numbers)
Summary · context
Seventeen nonmenopausal women with symptomatic uterine myomas, diagnosed by clinical examination and confirmed by pelvic ultrasonography, were treated with a delayed-release microcapsule preparation of D-Trp-6-LH-RH (Decapeptyl) injected intramuscularly, every 28 days.
Summary · context
The microcapsules were designed to release 100 micrograms/day for 30 days.
Summary · context
The mean duration of treatment was 4.7 months (range, 1-11).
Report a problemFND-0256529907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.